Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy.

While RNA interference (RNAi) therapy has demonstrated significant potential for cancer treatment, the effective and safe systemic delivery of RNAi agents such as small interfering RNA (siRNA) into tumor cells in vivo remains challenging. We herein reported a unique multistaged siRNA delivery nanoparticle (NP) platform, which is comprised of (i) a polyethylene glycol (PEG) surface shell, (ii) a sharp tumor microenvironment (TME) pH-responsive polymer that forms the NP core, and (iii) charge-mediated complexes of siRNA and tumor cell-targeting- and penetrating-peptide-amphiphile (TCPA) that are encapsulated in the NP core. When the rationally designed, long circulating polymeric NPs accumulate in tumor tissues after intravenous administration, the targeted siRNA-TCPA complexes can be rapidly released via TME pH-mediated NP disassembly for subsequent specific targeting of tumor cells and cytosolic transport, thus achieving efficient gene silencing. In vivo results further demonstrate that the multistaged NP delivery of siRNA against bromodomain 4 (BRD4), a recently discovered target protein that regulates the development and progression of prostate cancer (PCa), can significantly inhibit PCa tumor growth.

[1]  William Y. Kim,et al.  Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Jin-Zhi Du,et al.  Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. , 2012, ACS nano.

[3]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[4]  Q. Ping,et al.  Sequential intra-intercellular nanoparticle delivery system for deep tumor penetration. , 2014, Angewandte Chemie.

[5]  Mauro Ferrari,et al.  An injectable nanoparticle generator enhances delivery of cancer therapeutics , 2016, Nature Biotechnology.

[6]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[7]  V. Préat,et al.  RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. , 2012, Molecular pharmaceutics.

[8]  Xian‐Zheng Zhang,et al.  Controlled peptide coated nanostructures via the self-assembly of functional peptide building blocks , 2012 .

[9]  Shwu‐Yuan Wu,et al.  Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. , 2013, Molecular cell.

[10]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[11]  L. Patterson,et al.  RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis , 2012, Cancers.

[12]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[13]  Jonathan Rasmussen,et al.  Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy. , 2017, ACS nano.

[14]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[15]  Qingqing Yang,et al.  Multistage Nanovehicle Delivery System Based on Stepwise Size Reduction and Charge Reversal for Programmed Nuclear Targeting of Systemically Administered Anticancer Drugs , 2015 .

[16]  Omid C Farokhzad,et al.  Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy. , 2016, Angewandte Chemie.

[17]  M. Sporn,et al.  The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.

[18]  Robert Langer,et al.  Impact of nanotechnology on drug delivery. , 2009, ACS nano.

[19]  Ronnie H. Fang,et al.  Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery , 2014, Nano letters.

[20]  Leaf Huang,et al.  Multistage Delivery Technologies: Multifunctional, Interdisciplinary Approaches to Nanomedicine. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[22]  Jun Wang,et al.  Smart Superstructures with Ultrahigh pH-Sensitivity for Targeting Acidic Tumor Microenvironment: Instantaneous Size Switching and Improved Tumor Penetration. , 2016, ACS nano.

[23]  U. Schubert,et al.  Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. , 2010, Angewandte Chemie.

[24]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[25]  Yu-cheng Tseng,et al.  Lipid-based systemic delivery of siRNA. , 2009, Advanced drug delivery reviews.

[26]  F. Howe,et al.  Why are cancers acidic? A carrier-mediated diffusion model for H+ transport in the interstitial fluid. , 2001, Novartis Foundation symposium.

[27]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[28]  Zhen Gu,et al.  Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. , 2014, Chemical Society reviews.

[29]  Baran D. Sumer,et al.  A Broad Nanoparticle-Based Strategy for Tumor Imaging by Nonlinear Amplification of Microenvironment Signals , 2013, Nature materials.

[30]  Izhak Haviv,et al.  Co-evolution of tumor cells and their microenvironment. , 2009, Trends in genetics : TIG.

[31]  Jinho Park,et al.  Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy , 2012, Theranostics.

[32]  Dai Fukumura,et al.  Multistage nanoparticle delivery system for deep penetration into tumor tissue , 2011, Proceedings of the National Academy of Sciences.

[33]  Jinming Gao,et al.  Tunable, ultrasensitive pH-responsive nanoparticles targeting specific endocytic organelles in living cells. , 2011, Angewandte Chemie.

[34]  Daniel S. Kohane,et al.  Photoswitchable nanoparticles for in vivo cancer chemotherapy , 2013, Proceedings of the National Academy of Sciences.

[35]  J. Brady,et al.  The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. , 2005, Molecular cell.

[36]  Y. Lim,et al.  Controlled bioactive nanostructures from self-assembly of peptide building blocks. , 2007, Angewandte Chemie.

[37]  Jill P. Mesirov,et al.  Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Oncogene ID4 , 2012, Science Translational Medicine.

[38]  Noritada Kaji,et al.  Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. , 2011, Biomaterials.

[39]  Qiang Zhang,et al.  Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment , 2017, Theranostics.

[40]  Xiaoyuan Chen,et al.  Hierarchical Targeting Strategy for Enhanced Tumor Tissue Accumulation/Retention and Cellular Internalization , 2016, Advanced materials.

[41]  Jin-Zhi Du,et al.  Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. , 2011, Journal of the American Chemical Society.

[42]  Jun Wang,et al.  Matrix metalloproteinase 2-responsive micelle for siRNA delivery. , 2014, Biomaterials.

[43]  Mark E. Davis,et al.  Clinical experiences with systemically administered siRNA-based therapeutics in cancer , 2015, Nature Reviews Drug Discovery.

[44]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[45]  I. Wistuba,et al.  Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment , 2015, Proceedings of the National Academy of Sciences.

[46]  Zhen Gu,et al.  Programmable nanomedicine: synergistic and sequential drug delivery systems. , 2015, Nanoscale.

[47]  Song Shen,et al.  Tumor Acidity-Sensitive Polymeric Vector for Active Targeted siRNA Delivery. , 2015, Journal of the American Chemical Society.

[48]  Zheng-Rong Lu,et al.  Targeted Dual pH‐Sensitive Lipid ECO/siRNA Self‐Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy , 2016, Advanced healthcare materials.

[49]  Tristan Barrett,et al.  Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes , 2009, Nature Medicine.

[50]  Leaf Huang,et al.  In vivo gene delivery by nonviral vectors: overcoming hurdles? , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  Daniel Anderson,et al.  Delivery materials for siRNA therapeutics. , 2013, Nature materials.

[52]  Xiaoyuan Chen,et al.  Stimuli-Responsive Programmed Specific Targeting in Nanomedicine. , 2016, ACS nano.

[53]  Robert Langer,et al.  Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures , 2017, Expert opinion on drug delivery.

[54]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[55]  R. Raines,et al.  Internalization of cationic peptides: the road less (or more?) traveled , 2006, Cellular and Molecular Life Sciences CMLS.

[56]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[57]  Qiang Zhou,et al.  Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. , 2005, Molecular cell.

[58]  Jun Wang,et al.  Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy , 2016, Proceedings of the National Academy of Sciences.